Shailendra Dwivedi to Ovarian Neoplasms
This is a "connection" page, showing publications Shailendra Dwivedi has written about Ovarian Neoplasms.
Connection Strength
1.296
-
KRCC1: A potential therapeutic target in ovarian cancer. FASEB J. 2020 02; 34(2):2287-2300.
Score: 0.404
-
Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
Score: 0.312
-
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. Gynecol Oncol. 2025 Dec; 203:158-164.
Score: 0.152
-
Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth. Adv Sci (Weinh). 2022 11; 9(31):e2200491.
Score: 0.122
-
MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep. 2020 10 05; 21(10):e48483.
Score: 0.106
-
Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis. Mol Cancer Res. 2019 06; 17(6):1378-1390.
Score: 0.096
-
MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
Score: 0.084
-
BMI1, a new target of CK2a. Mol Cancer. 2017 03 07; 16(1):56.
Score: 0.021